Biocartis

Generaal De Wittelaan 11

2800 Mechelen

BE

Biocartis

Foundation date

02/07/2010

Sector

#Medical Technology

Subsector

Therapeutic areas

Biocartis is an innovative molecular diagnostics company committed to revolutionize molecular testing with its unique proprietary IdyllaTM platform. We provide next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and the healthcare industry, with a focus on oncology.

Biocartis’ proprietary molecular diagnostics (MDx) IdyllaTM platform is a fully automated sample-to-result, real-time PCR system that offers accurate, highly reliable molecular information from virtually any biological sample, in virtually any setting, allowing fast and effective treatment selection and treatment progress monitoring.

Upcoming events

Latest news

  • argenx reports topline results from ADVANCE-SC study of VYVGART Hytrulo in primary immune thrombocytopenia

    21 hours ago

  • Biocartis Holdings Inc.: Recapitalization completed and product portfolio expansion

    Wednesday November 22nd 2023

  • argenx announces European Commission approval of subcutaneous VYVGART® (efgartigimod alfa) for generalized myasthenia gravis

    Thursday November 16th 2023